Literature DB >> 21097496

Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Ryutaro Asano1, Keiko Ikoma, Ippei Shimomura, Shintaro Taki, Takeshi Nakanishi, Mitsuo Umetsu, Izumi Kumagai.   

Abstract

Diabodies (Dbs) and tandem single-chain variable fragments (taFv) are the most widely used recombinant formats for constructing small bispecific antibodies. However, only a few studies have compared these formats, and none have discussed their binding kinetics and cross-linking ability. We previously reported the usefulness for cancer immunotherapy of a humanized bispecific Db (hEx3-Db) and its single-chain format (hEx3-scDb) that target epidermal growth factor receptor and CD3. Here, we converted hEx3-Db into a taFv format to investigate how format affects the function of a small bispecific antibody; our investigation included a cytotoxicity assay, surface plasmon resonance spectroscopy, thermodynamic analysis, and flow cytometry. The prepared taFv (hEx3-taFv) showed an enhanced cytotoxicity, which may be attributable to a structural superiority to the diabody format in cross-linking target cells but not to differences in the binding affinities of the formats. Comparable cross-linking ability for soluble antigens was observed among hEx3-Db, hEx3-scDb, and hEx3-taFv with surface plasmon resonance spectroscopy. Furthermore, drastic increases in cytotoxicity were found in the dimeric form of hEx3-taFv, especially when the two hEx3-taFv were covalently linked. Our results show that converting the format of small bispecific antibodies can improve their function. In particular, for small bispecific antibodies that target tumor and immune cells, a functional orientation that avoids steric hindrance in cross-linking two target cells may be important in enhancing the growth inhibition effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097496      PMCID: PMC3023476          DOI: 10.1074/jbc.M110.172957

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

Authors:  S M Kipriyanov; G Moldenhauer; J Schuhmacher; B Cochlovius; C W Von der Lieth; E R Matys; M Little
Journal:  J Mol Biol       Date:  1999-10-15       Impact factor: 5.469

Review 2.  Recombinant bispecific antibodies for cancer therapy.

Authors:  Roland E Kontermann
Journal:  Acta Pharmacol Sin       Date:  2005-01       Impact factor: 6.150

3.  Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody.

Authors:  F Arakawa; M Kuroki; M Kuwahara; T Senba; H Ozaki; Y Matsuoka; Y Misumi; H Kanda; T Watanabe
Journal:  J Biochem       Date:  1996-09       Impact factor: 3.387

4.  Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.

Authors:  Ryutaro Asano; Yukiko Sone; Koki Makabe; Kouhei Tsumoto; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

5.  Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

Authors:  A M McCall; G P Adams; A R Amoroso; U B Nielsen; L Zhang; E Horak; H Simmons; R Schier; J D Marks; L M Weiner
Journal:  Mol Immunol       Date:  1999-05       Impact factor: 4.407

6.  Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.

Authors:  Bernd Schlereth; Iduna Fichtner; Grit Lorenczewski; Petra Kleindienst; Klaus Brischwein; Antonio da Silva; Peter Kufer; Ralf Lutterbuese; Ilse Junghahn; Sabine Kasimir-Bauer; Pauline Wimberger; Rainer Kimmig; Patrick A Baeuerle
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

7.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Authors:  Matthew K Robinson; Mohan Doss; Calvin Shaller; Deepa Narayanan; James D Marks; Lee P Adler; Dinko E González Trotter; Gregory P Adams
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

8.  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

Authors:  Michael Mølhøj; Sandrine Crommer; Klaus Brischwein; Doris Rau; Mirnaalini Sriskandarajah; Patrick Hoffmann; Peter Kufer; Robert Hofmeister; Patrick A Baeuerle
Journal:  Mol Immunol       Date:  2006-11-02       Impact factor: 4.407

9.  Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.

Authors:  Lillian S Shahied; Yong Tang; R Katherine Alpaugh; Robert Somer; Dana Greenspon; Louis M Weiner
Journal:  J Biol Chem       Date:  2004-10-07       Impact factor: 5.157

10.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.

Authors:  X Y Pei; P Holliger; A G Murzin; R L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

View more
  11 in total

1.  Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.

Authors:  Ryutaro Asano; Yuri Kuroki; Sachiko Honma; Mihoko Akabane; Shunsuke Watanabe; Shinzo Mayuzumi; Shuichi Hiyamuta; Izumi Kumagai; Koji Sode
Journal:  MAbs       Date:  2018-07-09       Impact factor: 5.857

Review 2.  An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Authors:  Patrick C Gedeon; Bryan D Choi; Tiffany R Hodges; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Expert Rev Clin Pharmacol       Date:  2013-07       Impact factor: 5.045

3.  Screening for a single-chain variable-fragment antibody that can effectively neutralize the cytotoxicity of the Vibrio parahaemolyticus thermolabile hemolysin.

Authors:  Rongzhi Wang; Sui Fang; Dinglong Wu; Junwei Lian; Jue Fan; Yanfeng Zhang; Shihua Wang; Wenxiong Lin
Journal:  Appl Environ Microbiol       Date:  2012-05-04       Impact factor: 4.792

4.  Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Authors:  Ryutaro Asano; Ippei Shimomura; Shota Konno; Akiko Ito; Yosuke Masakari; Ryota Orimo; Shintaro Taki; Kyoko Arai; Hiromi Ogata; Mai Okada; Shozo Furumoto; Masayoshi Onitsuka; Takeshi Omasa; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Mitsuo Umetsu; Izumi Kumagai
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.

Authors:  Mahiuddin Ahmed; Ming Cheng; Irene Y Cheung; N K Cheung
Journal:  Oncoimmunology       Date:  2015-04-27       Impact factor: 8.110

6.  Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Authors:  Ryutaro Asano; Noriaki Koyama; Yasuyo Hagiwara; Yosuke Masakari; Ryota Orimo; Kyoko Arai; Hiromi Ogata; Shozo Furumoto; Mitsuo Umetsu; Izumi Kumagai
Journal:  FEBS Open Bio       Date:  2016-05-16       Impact factor: 2.693

Review 7.  Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.

Authors:  Pei-Pei Ren; Ming Li; Tian-Fang Li; Shuang-Yin Han
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

8.  Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.

Authors:  Ryutaro Asano; Keisuke Nagai; Koki Makabe; Kento Takahashi; Takashi Kumagai; Hiroko Kawaguchi; Hiromi Ogata; Kyoko Arai; Mitsuo Umetsu; Izumi Kumagai
Journal:  Oncotarget       Date:  2018-02-14

9.  A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.

Authors:  Shintaro Taki; Haruhiko Kamada; Masaki Inoue; Kazuya Nagano; Yohei Mukai; Kazuma Higashisaka; Yasuo Yoshioka; Yasuo Tsutsumi; Shin-ichi Tsunoda
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

10.  Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method.

Authors:  Hideaki Sanada; Kazuki Kobayashi; Kenji Oyama; Takamitsu Maru; Takeshi Nakanishi; Mitsuo Umetsu; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.